The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.
Fully understand the study and voluntarily sign the informed consent form.
Male or female 18-70 years of age.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
Histologically confirmed recurrent or metastatic neuroendocrine carcinoma
Medical history, computed tomography or magnetic resonance imaging results indicate that existence of the central nervous system metastases;
Any other malignancy within 5 years.
participants were deemed unsuitable for participating in the study by the investigator for any reasons.